VINTUM 4.5

bt_bb_section_bottom_section_coverage_image
https://www.larivinpharma.com/wp-content/uploads/2024/04/VINTUM-4.5.jpg

Composition

Win Tough Infections…

VINTUM 4.5 gm
Piperacillin 4gm & Tazobactam 500 mg (IV) Injection

Tagline:
Broad-Spectrum Defense Against Complex Infections

Key Features:

  • Piperacillin: Acts by binding to penicillin-binding proteins (PBPs) on the bacterial cell wall, inhibiting cell wall synthesis, which is essential for bacterial growth and replication.
  • Tazobactam: A potent extended-spectrum beta-lactamase inhibitor that protects Piperacillin from degradation by beta-lactamase enzymes, extending its spectrum of activity against resistant bacteria.
  • Comprehensive Coverage: Piperacillin/Tazobactam is highly effective against a wide range of bacteria, making it the drug of choice for the treatment of complicated skin and soft tissue infections (cSSTIs).

Indication:
Vintum 4.5 gm is indicated for the treatment of a variety of severe bacterial infections, particularly those caused by resistant organisms, including:

  • Complicated Intra-abdominal Infections: Including peritonitis and abscesses.
  • Peritonitis: Inflammation of the peritoneum, often due to infection.
  • Appendicitis: Infection and inflammation of the appendix.
  • Diabetic Foot Ulcer: Infections associated with diabetic foot wounds.
  • Ventilator-Associated Pneumonia (VAP): Pneumonia that occurs in patients receiving mechanical ventilation.
  • Febrile Neutropenia: Treatment of infections in patients with low neutrophil counts, often due to chemotherapy.
  • Nosocomial Pneumonia: Hospital-acquired pneumonia, including infections caused by resistant bacteria.
  • Burns: Infections associated with burn wounds.
  • Abscess: Localized collections of pus due to infection.
  • Sepsis: Life-threatening infections that spread throughout the body.
  • Complicated Urinary Tract Infections (cUTIs): UTIs that are difficult to treat due to resistance or underlying conditions.

Mode of Action:

  • Piperacillin: Inhibits bacterial cell wall synthesis by binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall. This action prevents the cross-linking of peptidoglycan chains, which are necessary for bacterial cell wall strength and rigidity, leading to bacterial cell lysis and death.
  • Tazobactam: Extends the antibacterial activity of Piperacillin by inhibiting beta-lactamase enzymes that would otherwise degrade Piperacillin. This combination ensures a broader spectrum of activity, particularly against beta-lactamase-producing bacteria.

How to Take Vintum 4.5 gm:

  • Administration: Vintum 4.5 gm is administered as an intravenous (IV) infusion. The preparation and administration should be carried out by a healthcare professional in a clinical setting.
  • Dosage Frequency: The standard dosage is 4.5 gm every 8 hours. The exact duration and frequency of treatment depend on the severity of the infection and the patient’s response.
  • Reconstitution: The injection should be reconstituted with the appropriate diluent before administration, following the manufacturer’s instructions or healthcare provider’s guidance.

Dosage:

  • Standard Dosage: 4.5 gm of Piperacillin/Tazobactam administered every 8 hours via intravenous infusion. The duration of treatment depends on the type and severity of the infection.

Possible Side Effects:
While Vintum 4.5 gm is generally well-tolerated, some patients may experience side effects. Common side effects include:

  • Gastrointestinal Issues: Diarrhea, nausea, vomiting, or abdominal pain.
  • Injection Site Reactions: Pain, redness, or swelling at the injection site.
  • Headache: Some patients may experience mild to moderate headaches.
  • Allergic Reactions: Rash, itching, or hives. Severe allergic reactions (anaphylaxis) are rare but require immediate medical attention.
  • Hematologic Changes: Rarely, Piperacillin/Tazobactam may cause changes in blood counts, such as leukopenia, thrombocytopenia, or anemia. Regular monitoring may be required during prolonged therapy.
  • Electrolyte Imbalance: Monitor for potential imbalances, particularly in patients receiving long-term therapy.
  • Superinfection: Prolonged use of antibiotics can sometimes lead to the overgrowth of non-susceptible organisms, such as fungi.

Precautions:

  • Renal Function: Use with caution in patients with renal impairment. Dose adjustments may be necessary, and regular monitoring of renal function is recommended.
  • Liver Function: Regular monitoring may be necessary in patients with pre-existing liver conditions.
  • Bleeding Risk: Piperacillin may increase the risk of bleeding. Monitor patients for signs of bleeding, especially those on anticoagulants.
  • Drug Interactions: Inform your healthcare provider of all medications you are taking, as Piperacillin/Tazobactam can interact with certain drugs, potentially affecting their efficacy.

Consult Your Doctor:

  • Before starting Vintum 4.5 gm if you have any known allergies, particularly to penicillins, cephalosporins, or beta-lactamase inhibitors, or if you have kidney or liver disease.
  • If you experience any severe or unusual symptoms, particularly signs of an allergic reaction, gastrointestinal distress, or bleeding.
  • For guidance on managing your condition and to discuss any concerns regarding your treatment plan. 

Disclaimer: This information is for general knowledge only and should not be considered medical advice. Always consult with a healthcare professional for personalized guidance.

https://www.larivinpharma.com/wp-content/uploads/2020/06/large_blue_triangle_04.png
https://www.larivinpharma.com/wp-content/uploads/2024/04/VINTUM-4.5.jpg
https://www.larivinpharma.com/wp-content/uploads/2020/04/small_blue_triangle.png
https://www.larivinpharma.com/wp-content/uploads/2020/06/large_blue_triangle_01.png
https://www.larivinpharma.com/wp-content/uploads/2023/03/larivin-pharma-footer-icon-160x160.png
No.32, First Floor, Varadharaja Swamy Nagar, Sri Krishna Nagar, Maduravoyal, Chennai, Tamil Nadu 600095

© 2023 Larivin Pharma Private Limited. All rights reserved